SLC22A5 and central nervous system cancer: An analysis with the use of Human Protein Atlas (https://www.proteinatlas.org/humanproteome/pathology), a visualization tool for among other things The Cancer Genome Atlas (TCGA) datasets, demonstrates SLC22A5 expression in several cancers, including glioma, breast cancer and endometrial cancer, with the highest level of expression in renal cancer.